What Immunization Providers Need to Know about Vaccine Safety and Talking to Concerned Parents

Содержание

Слайд 2

Overview of Presentation Overview of the U.S. vaccine safety system Updates

Overview of Presentation

Overview of the U.S. vaccine safety system
Updates on a

number of current vaccine safety issues
Vaccines and autism (April 2009 edition)
What are parents concerned about, and how to better address those concerns
Слайд 3

Vaccine Safety When the vaccine is under development, studies are done

Vaccine Safety

When the vaccine is under development, studies are done

to find out if it is safe and effective
FDA review: if safe and effective, vaccine can be licensed
Other issues (manufacturing etc.) also considered by FDA
Ongoing monitoring by both CDC and FDA and by the manufacturer after licensure
Post-licensure studies by the manufacturer
Vaccine Adverse Event Reporting System (VAERS)
Special studies
If vaccine safety issues are identified, actions are taken
Слайд 4

What Do VAERS Reports Mean? VAERS has led to early identification

What Do VAERS Reports Mean?

VAERS has led to early identification of

serious adverse events
Not every adverse event caused by the vaccine is reported to VAERS
Just because something is reported to VAERS, it doesn’t mean it’s caused by the vaccine
Publicly accessible database: http://vaers.hhs.gov/info.htm
Слайд 5

How Do We Decide What We Are Going to Worry About?

How Do We Decide What We Are Going to Worry About?

Consistent

pattern of clinical findings
Biologic plausibility
Consistency of findings in other studies
Clustering of cases in time after vaccination, especially in a “biologically plausible” interval
Observed cases > expected cases
Calculations require knowing what the incidence of the condition is, and how many doses of vaccine have been given
Слайд 6

A Faster Approach to Vaccine Safety Studies Alternative to traditional post-licensure

A Faster Approach to Vaccine Safety Studies

Alternative to traditional post-licensure vaccine

safety study methods, which generally take years to complete
The Rapid Cycle Analysis approach in the Vaccine Safety Datalink:
Tests specific hypotheses with well-defined outcomes
Each week, evaluate the number of events in vaccinated persons
Compare it to the expected number of events based on a comparison group
Weekly analyses with statistical adjustment for multiple looks

Lieu TA, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007 Oct;45:S89-95.

Слайд 7

Meningococcal Conjugate Vaccine and Guillain-Barré Syndrome VAERS: 24 confirmed reports among

Meningococcal Conjugate Vaccine and Guillain-Barré Syndrome

VAERS: 24 confirmed reports among vaccine

recipients
2 among persons 11-14 years of age
20 among persons 15-19 years of age
Observed cases > expected cases for 15-19 year olds
Calculation assumes complete reporting and administration of all doses of vaccine distributed
Benefits of vaccination still outweigh risks, even if magnitude of risk is greater than that observed to date

ACIP, October 2007

Слайд 8

Timing of Onset of GBS following Meningococcal Conjugate Vaccine Onset intervals

Timing of Onset of GBS following Meningococcal Conjugate Vaccine

Onset intervals 2-33

days
Mean 17.4 days
Median 14.5 days
Слайд 9

Update on Safety of Varicella Vaccine Varicella vaccine strain can establish

Update on Safety of Varicella Vaccine

Varicella vaccine strain can establish

latency like wildtype varicella and later reactivate as zoster
Available data suggest that risk of reactivation less than for wildtype virus
Слайд 10

Establishment of VZV Latency in Sensory-Nerve Ganglia Kimberlin D, Whitley R. N Engl J Med 2007;356:1338-1343

Establishment of VZV Latency in Sensory-Nerve Ganglia

Kimberlin D, Whitley R. N

Engl J Med 2007;356:1338-1343
Слайд 11

Herpes Zoster among Recipients of Varicella Vaccine VAERS: 981 reports of

Herpes Zoster among Recipients of Varicella Vaccine

VAERS: 981 reports of

herpes zoster
47 of 981 were hospitalized
Median age: 2.5 years (range 12 mo-12 yr)
Median interval from vaccination to zoster: 7.3 months (range 3 days-4.3 years)
21 of 43 were on the face
Of 17 with viruses typed, 10 vaccine type
Of 12 episodes associated with meningitis, 4 vaccine type
Слайд 12

Слайд 13

Judicial Watch Investigates Side-Effects of HPV Vaccine Wed, 05/14/2008 - 14:05

Judicial Watch Investigates Side-Effects of HPV Vaccine

Wed, 05/14/2008 - 14:05 —

gstasiewicz
"The FDA adverse event reports on the HPV vaccine read like a catalog of horrors. Any state or local government now beset by Merck’s lobbying campaigns to mandate this HPV vaccine for young girls ought to take a look at these adverse health reports." -Tom Fitton
http://www.judicialwatch.org/story/2008/may/judicial-watch-investigates-side-effects-hpv-vaccine
Слайд 14

Adverse Events and HPV Vaccine: Summary Over 21 million doses distributed

Adverse Events and HPV Vaccine: Summary

Over 21 million doses distributed
As of

August 31, 2008, 10,326 VAERS reports following Gardasil vaccination
6% serious events
27 deaths in the U.S. reported to VAERS, without a common pattern that would suggest they were caused by the vaccine
Cases of Guillain-Barre syndrome reported; to date, no evidence that Gardasil has increased the rate of GBS above that expected
Based on the review of available information by FDA and CDC, Gardasil continues to be safe and effective, and its benefits continue to outweigh its risks.

http://www.cdc.gov/vaccinesafety/vaers/gardasil.htm

Слайд 15

Reports of Death Following HPV Vaccine 20 U.S. death reports; unable to follow up 7

Reports of Death Following HPV Vaccine

20 U.S. death reports; unable to

follow up 7
Слайд 16

Syncope (Fainting) following HPV Vaccine Increased reporting of syncope among vaccinees

Syncope (Fainting) following HPV Vaccine

Increased reporting of syncope among vaccinees
Although usually

not serious, syncope can result in falls, which sometimes cause serious injuries, especially head injuries
Syncope recognized to occur following vaccination, especially among adolescents and adults
Слайд 17

General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization

General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization

Practices (ACIP)

“…, although syncopal episodes are uncommon … vaccine providers should strongly consider observing patients for 15 minutes after they are vaccinated. If syncope develops, patients should be observed until symptoms resolve.”

MMWR 2006; 55 (No. RR-15)

Слайд 18

Intussusception and RotaTeq® 9.1 million doses distributed (March 2006- August 31,

Intussusception and RotaTeq®

9.1 million doses distributed (March 2006- August 31, 2007)*
VAERS:

160 confirmed intussusception reports
47 reports with onset 1-21 days after vaccine
27 of 47 were within 1-7 days
Observed cases < expected cases, assuming 75% of intussusception cases reported to VAERS and 75% of distributed vaccine administered

Haber, Pediatrics, 2008

Слайд 19

Adverse Reactions Following MMRV and MMR+V Fever is more common in

Adverse Reactions Following MMRV and MMR+V

Fever is more common in the

5-12 days after vaccination following MMRV (22%) than following MMR+V (15%)
Data from CDC Vaccine Safety Datalink sites indicate the rate of febrile seizures following MMRV (9 per 10,000 vaccinated ) was approximately 2 times higher than among those receiving MMR+V at the same visit (4 per 10,000 vaccinated)
Merck postlicensure surveillance has identified a similar trend
Слайд 20

Temporal Distribution of Seizures after MMRV Vaccination Days Post-MMRV Vaccine Number

Temporal Distribution of Seizures after MMRV Vaccination

Days Post-MMRV Vaccine

Number of Seizures

(2/06-9/07, after

47,137 vaccine visits)

Klein, ACIP presentation, February 2008

Слайд 21

Thimerosal and Autism: What Does the Science Show? Ecologic studies: autism

Thimerosal and Autism: What Does the Science Show?

Ecologic studies: autism does not

go down when thimerosal is removed from childhood vaccines
Epidemiologic studies: well-designed studies demonstrate no association between thimerosal exposure from vaccines and autism
Biochemical studies and animal models interesting but uninformative
Слайд 22

Children Receiving Autism Services by Quarter, California, 2002-2007 California Department of Developmental Services

Children Receiving Autism Services by Quarter, California, 2002-2007

California Department of Developmental

Services
Слайд 23

Vaccines and Autism, Still MMR and autism (1998) Thimerosal and autism

Vaccines and Autism, Still

MMR and autism (1998)
Thimerosal and autism (2001)
Simultaneous administration

of multiple vaccines and the “one size fits all” immunization schedule (2007)
Mitochondrial disorders (2008)
Слайд 24

Vaccines and Autism: Context Heuristics and biases Distrust of government Unanswered

Vaccines and Autism: Context

Heuristics and biases
Distrust of government
Unanswered questions about autism

and real needs of families
Advocacy
Litigation
The Internet
Слайд 25

“Why doesn’t CDC study autism rates in unvaccinated children?” Almost all

“Why doesn’t CDC study autism rates in unvaccinated children?”

Almost all children

in the U.S. have received at least some vaccines; only 3 per 1000 children have received no vaccines
Although recognized autism spectrum disorders more common than previously reported (up to 6 per 1000), disease is infrequent enough that a large population needed to identify sufficient cases for a study
Unvaccinated children probably very different from other children in terms of:
Health care utilization
Other exposures
Слайд 26

Number of Vaccines in the Routine Childhood and Adolescent Immunization Schedule

Number of Vaccines in the Routine Childhood and Adolescent Immunization Schedule

1985

1995

2006

Measles
Rubella
Mumps
Diphtheria
Tetanus
Pertussis
Polio
Hib

(infant)
HepB
Varicella
Pneumococcal disease
Influenza
Meningococcal disease
HepA
Rotavirus
HPV

Measles
Rubella
Mumps
Diphtheria
Tetanus
Pertussis
Polio
Hib (infant)
HepB
Varicella

Measles
Rubella
Mumps
Diphtheria
Tetanus
Pertussis
Polio

7

10

16

Слайд 27

Recommended Schedule for Persons Aged 0-6 Years, U.S.

Recommended Schedule for Persons Aged 0-6 Years, U.S.

Слайд 28

Current Parent Concerns Focus groups with first time mothers in 3

Current Parent Concerns

Focus groups with first time mothers in 3 cities:

Chicago, Portland, and Richmond
Most participants had high levels of knowledge and of concern
Many participants know someone who is not fully vaccinating their child
All vaccines are not seen by many parents as equally important to protect children
Unclear what impact these concerns have had on immunization coverage

Preliminary report, NCIRD Office of Communication Science

Слайд 29

What Parents Are Concerned About (2008) It is painful for children

What Parents Are Concerned About (2008)

It is painful for children to

get so many shots during one doctors visit (43%)
My child getting too many vaccines in one doctor’s visit (40%)
Vaccines causing fevers in my child (36%)
The ingredients in vaccines are unsafe (34%)
Children get too many vaccines in the first two years of life (33%)
Vaccines may cause learning disabilities (such as autism) (33%)
Vaccines are not tested enough for safety (32%)

HealthStyles, 2008

Слайд 30

Слайд 31

Why Do We Give Vaccines at the Ages We Do? To

Why Do We Give Vaccines at the Ages We Do?

To provide

protection from vaccine preventable diseases at the earliest age possible, or before periods of increased risk
Given concurrently with other vaccines to coincide with established schedule of well-child visits
Reflect ages at which vaccines are tested in clinical trials, and generally consistent with labeling
Слайд 32

Advisory Committee on Immunization Practices Evidence-based recommendations based on: Licensed indications

Advisory Committee on Immunization Practices

Evidence-based recommendations based on:
Licensed indications and schedule
Burden

of disease to be prevented
Efficacy and effectiveness of the vaccine
Safety of the vaccine
Feasibility of programmatic implementation
Equity in access to vaccine and good use of public funds
Recommendations of other groups
Schedule represents a summation of individual vaccine recommendations, including recommendations for simultaneous administration
Слайд 33

Missed Opportunities Definition: Healthcare encounter in which a child is eligible

Missed Opportunities

Definition: Healthcare encounter in which a child is eligible to

receive a vaccination but is not vaccinated
What causes missed opportunities?
Referrals from immunization provider
Deferrals of vaccination
Provider unaware that vaccines are due
Failure to provide simultaneous vaccinations
Inappropriate contraindications
Office policies/administrative barriers
Non-vaccinating health care providers
Слайд 34

Safety and Efficacy Issues Potentially Associated with the Schedule Data generally

Safety and Efficacy Issues Potentially Associated with the Schedule

Data generally available

on concurrent administration at licensure
Interference between concurrently administered vaccines theoretically possible but generally not observed
Need for spacing of live virus vaccines
Safety or efficacy issues associated with concurrent or antecedent exposure to vaccine components (e.g., diphtheria toxoid-containing vaccines)
Cumulative exposure to vaccine components
Слайд 35

Outpatient Visits for Fever by Day after Vaccine at Northern California

Outpatient Visits for Fever by Day after Vaccine at Northern California

Kaiser Permanente: 1995-2008

Vaccine Safety Datalink; Immunization Safety Office, CDC

Слайд 36

Data on Simultaneous Administration for a Licensed Vaccine: ROTARIX 484 healthy

Data on Simultaneous Administration for a Licensed Vaccine: ROTARIX

484 healthy infants

randomized into two groups
All received Pediarix, PCV7, and ActHib at 2, 4, and 6 months and either ROTARIX concurrently at 2 and 4 months or separately at 3 and 5 months
Co-administration: n=249
Separate administration: n=235
Prespecified criteria for noninferiority of antibody response met for all antigens

Abu-Elyazeed et al, ICAAC 2007

Слайд 37

The Science of Studying More than One Thing at a Time

The Science of Studying More than One Thing at a Time

Rapid

advances in multiple fields of biology have made it possible to study complex biological reactions at the cellular level
These new “systems biology” approaches are beginning to be applied to questions about vaccines
Слайд 38

Other Issues Recommendations and requirements – should everything that is recommended

Other Issues

Recommendations and requirements – should everything that is recommended be

required?
Public health vs. individual decisions
Different perceptions of benefits associated with prevention of some vaccine-preventable diseases
The expectation of “personalized medicine”
Are some children uniquely susceptible to adverse events?
Слайд 39

Is Our Immunization Schedule “One Size Fits All”? Contraindications and precautions

Is Our Immunization Schedule “One Size Fits All”?

Contraindications and precautions do

provide guidance for decision-making
Flexibility in timing within the recommended schedule
Some children are vulnerable, and screening usually not possible
Vulnerable children can be protected -- with safer vaccines for everyone
Слайд 40

SMEI and “Vaccine Encephalopathy” Epileptic encephalopathies, without other specific cause identified,

SMEI and “Vaccine Encephalopathy”

Epileptic encephalopathies, without other specific cause identified, with

first seizure onset within 72 hours of vaccination
Cases ascertained by child neurologists in Australia and New Zealand 2002-2003
Diagnoses:
SMEI – 8 patients
SMEB – 4 patients
Lennox-Gastaut syndrome – 2 patients
Molecular analysis:
Heterozygous mutations of SCN1A in 11 of 14 cases

Berkovic et al, Lancet Neurology 2006

Слайд 41

What Determines Credibility? Low Concern Settings All other factors 15-20% Competence/

What Determines Credibility? Low Concern Settings

All other factors
15-20%

Competence/
Expertise
80-85%

Randall Hyer, NIC, 2005

Слайд 42

What Determines Credibility? High Concern Settings All other factors 15-20% Competence/

What Determines Credibility? High Concern Settings

All other factors
15-20%

Competence/
Expertise
15-20%

Honesty/openness
15-20%

Listening/caring/
Empathy
50%

Randall Hyer, NIC, 2005

Слайд 43

Measles Cases Reported to CDC/NCIRD January 1 to July 11, 2008

Measles Cases Reported to CDC/NCIRD January 1 to July 11, 2008

(N= 132)

San Diego, CA
Outbreak N=12
(CA =11, HI =1) Source=Switzerland, D5
Jan 25-Feb 16

Missaukee County, MI Outbreak, N=4 Source=Unknown, D5 Feb 29-Apr 8

Pima County, AZ Outbreak N=18 Source=Switzerland, D5
Feb 13-May 2

Los Angeles, CA N=2 Source=Unknown Mar 23-Apr 16

Fairfax, VA N=1 Source=India Feb 25

Milwaukee County, WI Outbreak, N=6 Source=China-H1
Mar 19-Apr 25

Nassau County, NY N=1, Source=Israel Apr 4

New York City, NY
N=27 Sources:
Israel (1)
Belgium (2) D4
Italy (1)
Other Import-
associated (10)
Source Unknown (13)
Jan 18-Jun 10

Honolulu, HI
N=4 Sources:
Italy (2)
China (1)
Philippines (1)
Feb 5-May 22

Pittsburgh, PA N=1 Source=Unknown Apr 12

Chicago, IL
N=1 Source=Switzerland Apr 17

Grant County, WA
Outbreak N=19
Source= Japan
Apr 12 - May 30

Vernon County, WI
N=1
Source=Germany
Apr 25

Scott County, AR
N=2
Source= Unknown
Feb 12-Feb 22

San Francisco, CA N=2, Sources:
India (1), Italy (1) Apr 18, Jun 22

D.C. N=1
Source Unknown Apr 20

Chaves Co, NM N=1, Unknown Mar 17

Baton Rouge , LA N=1, Russia May 14

Du Page Co, I L Outbreak N=27
Source=Italy, D4
May 15-Jun 25

Fulton Co, GA N=1 Pakistan May 14

Cass Co, MO N=1
Source Unknown Apr 7

Слайд 44

Invasive H. influenzae type B disease -- Minnesota, 2008 5 cases

Invasive H. influenzae type B disease -- Minnesota, 2008

5 cases of

invasive Hib disease in children <5 years of age; 1 death
Geographically dispersed and not epidemiologically linked
3 children had received no vaccinations because of parental refusal; 2 were partially vaccinated
Ongoing Hib vaccine shortage
Слайд 45

Where That Leaves Us When we do more than one thing

Where That Leaves Us

When we do more than one thing at

a time, it’s complicated - and we should acknowledge that
We need to help immunization providers help parents deal with a very complex set of decisions
Vaccination is the best way to protect children from 16 vaccine-preventable diseases